Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GFER | P55789 | 1/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.63 |
| ▸ | HTT | P42858 | 5/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 5/20 | 0.60 |
| ▸ | USP2 | O75604 | 3/20 | 0.60 |
| ▸ | GAA | P10253 | 3/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 4/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | RECQL | P46063 | 1/20 | 0.57 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.57 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27852868 | 0.84 | HTT (0.60) | GFERL3MBTL1NPSR1HTTALDH1A1 | |
| SCHEMBL19626762 | 0.83 | GFER (0.74) | GFERL3MBTL1NPSR1HTTALDH1A1 | |
| SCHEMBL956179 | 0.83 | ALDH1A1 (0.64) | GFERNPSR1HTTALDH1A1HPGD | |
| SCHEMBL19627019 | 0.80 | GFER (1.00) | GFERL3MBTL1NPSR1HTTALDH1A1 | |
| SCHEMBL27765617 | 0.80 | MAPT (0.61) | GFERNPSR1HTTALDH1A1HPGD | |
| SCHEMBL982911 | 0.76 | RECQL (0.66) | GFERHTTALDH1A1HPGDMAPT | |
| SCHEMBL8257849 | 0.76 | RECQL (0.70) | GFERL3MBTL1NPSR1HTTALDH1A1 | |
| SCHEMBL1020685 | 0.75 | RECQL (0.59) | GFERL3MBTL1HTTALDH1A1HPGD | |
| SCHEMBL10076588 | 0.74 | RECQL (0.68) | GFERL3MBTL1HTTALDH1A1HPGD | |
| SCHEMBL19626761 | 0.74 | HTT (1.00) | GFERHTTALDH1A1HPGDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11958833-B2 | Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2024-04-16 | — | — | US | disclosed |
| EP-4122929-A1 | NOVEL COMPOUNDS | Mission Therapeutics Limited (GB) | 2023-01-25 | — | — | EP | disclosed |
| EP-3390391-B1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2022-09-14 | — | — | EP | disclosed |
| US-20210380562-A1 | Novel Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2021-12-09 | — | — | US | disclosed |
| US-11130748-B2 | Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2021-09-28 | — | — | US | disclosed |
| CN-108368089-B | Deubiquitinase inhibitor | 特殊治疗有限公司 | 2021-07-06 | — | — | CN | disclosed |
| US-20200172516-A1 | Novel Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2020-06-04 | — | — | US | disclosed |
| EP-3390391-A1 | NOVEL COMPOUNDS | Mission Therapeutics Limited (GB) | 2018-10-24 | — | — | EP | disclosed |
| US-10000449-B2 | Bisarylsulfonamides useful in the treatment of inflammation and cancer | KANCERA AB (SE) | 2018-06-19 | — | — | US | disclosed |
| EP-2794009-B1 | BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER | KANCERA AB (SE) | 2017-08-30 | — | — | EP | disclosed |
| US-20090029999-A1 | Synephrine derivatives useful as anti-inflammatory agents | UNIVERSITEIT GENT (BE) | 2009-01-29 | — | — | US | disclosed |
| US-20080292585-A1 | Azonafide Derivatives, Methods for Their Production and Pharmaceutical Compositions Therefrom | UNIBIOSCREEN S.A. (BE) | 2008-11-27 | — | — | US | disclosed |
| EP-1981504-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES | NV Remynd (BE) | 2008-10-22 | — | — | EP | disclosed |
| EP-1963255-A1 | SYNEPHRINE DERIVATIVES USEFUL AS ANTI-INFLAMMATORY AGENTS | UNIVERSITEIT GENT (BE) | 2008-09-03 | — | — | EP | disclosed |
| EP-1960365-A2 | AZONAFIDE DERIVATIVES, METHODS FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS THEREFROM | Unibioscreen S.A. (BE) | 2008-08-27 | — | — | EP | disclosed |
| WO-2008061781-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES | NV REMYND (BE) | 2008-05-29 | — | — | WO | disclosed |
| WO-2007118899-A1 | HETEROCYCLIC ARYLSULPHONES SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5HT6 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007090617-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES | NV REMYND (BE) | 2007-08-16 | — | — | WO | disclosed |
| WO-2007071452-A1 | SYNEPHRINE DERIVATIVES USEFUL AS ANTI-INFLAMMATORY AGENTS | UNIVERSITEIT GENT (BE) | 2007-06-28 | — | — | WO | disclosed |
| WO-2007054292-A2 | AZONAFIDE DERIVATIVES, METHODS FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS THEREFROM | UNIBIOSCREEN S.A. (BE) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029999-A1 | Synephrine derivatives useful as anti-inflammatory agents | HRH1, HRH3, HRH2 | GFER 4294/4885L3MBTL1 4486/4885NPSR1 215/4885 |
| US-20210380562-A1 | Novel Compounds | USP30, USP20, USP10 | GFER 3562/4885L3MBTL1 608/4885NPSR1 4192/4885 |
| US-11130748-B2 | Compounds | USP30, USP20, USP10 | GFER 3423/4885L3MBTL1 593/4885NPSR1 4155/4885 |
| US-10000449-B2 | Bisarylsulfonamides useful in the treatment of inflammation and cancer | NFKBIA, IL6, LITAF | GFER 3175/4885L3MBTL1 4332/4885NPSR1 653/4885 |
| US-20080292585-A1 | Azonafide Derivatives, Methods for Their Production and Pharmaceutical Compositions Therefrom | AADAC, NOTUM, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | GFER 126/4885L3MBTL1 3808/4885NPSR1 4113/4885 |
| US-20200172516-A1 | Novel Compounds | USP30, USP20, USP10 | GFER 3562/4885L3MBTL1 608/4885NPSR1 4192/4885 |
| US-11958833-B2 | Compounds | USP30, USP20, USP10 | GFER 3423/4885L3MBTL1 593/4885NPSR1 4155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.